Driveline Relocation and Vacuum-Assisted Closure for Ventricular Assist Device Driveline Infections
Journal of Cardiovascular Development and Disease · 03.06.2025 · 12 (6) · 211
DOI: 10.3390/jcdd12060211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 03.06.2025. Verfasst von Mehmet Cahit Saricaoglu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Heart Center, Cebeci Hospitals, Ankara University School of Medicine, Dikimevi, Ankara 06340, Turkey. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Durable mechanical circulatory support (DMCS) infections remain a serious challenge. Ventricular assist device (VAD)-specific driveline infections (DLIs) are the most common type; however, no consensus exists on their surgical management. We aimed to define the incidence, risk factors, and microbiology of DLIs and discuss the surgical treatment modalities.
Methods
We retrospectively reviewed 90 patients who underwent a left or biventricular ventricular assist device (LVAD or BiVAD) implantation with either a HeartMate 2 (Abbott), HeartWare HVAD (Medtronic), or HeartMate 3 (Abbott) in a single center between 1 March 2011 and 30 May 2023.
Results
DLIs were detected in 20 (21.5%) patients during the follow-up. The mean duration of VAD support was 561.1 ± 833.2 days (1–4124 days), while it was 1277.9 ± 621.6 days in the DLI group. An extended duration of VAD support was associated with higher incidence rates of late-onset DLIs (p < 0.05). A younger age and lower plasma albumin levels were independent predictive factors for the risk of a DLI, with a hazard ratio of 9.77 (95%CI: 1.3–74.5) and 10.55 (95%CI: 1.40–79.35), respectively. The removal of the biofilm with velour and DL relocation through the rectus muscle combined with vacuum-assisted strategies (VAC) were performed in nine patients. One patient developed a recurrent infection, and another patient with a deep DLI subsequently received a heart transplant. No patient underwent a device exchange for an intractable DLI.
Conclusions
Our results suggest that DLIs are common infectious complications after VAD implantation, which endanger patient autonomy, and impair their quality of life and overall survival. A DL relocation through the rectus muscles and VAC strategies have a role in controlling DLIs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Heart Center, Cebeci Hospitals, Ankara University School of Medicine, Dikimevi, Ankara 06340, Turkey.
- Department of Infectious Disease and Clinical Microbiology, Ibni Sina Hospital, Ankara University School of Medicine, Ankara 06340, Turkey.
ORCID-Profile: Melisa Kandemir, Ali Fuat Karacuha, Alpay Azap, Ahmet Ruchan Akar
Zitieren
APA
Saricaoglu, M. C., Kandemir, M., Saricaoglu, E. M., Karacuha, A. F., Kadiroglu, E., Abdullahi, M. F., Inan, M. B., Azap, A., & Akar, A. R. (2025). Driveline Relocation and Vacuum-Assisted Closure for Ventricular Assist Device Driveline Infections. Journal of Cardiovascular Development and Disease, 12(6), 211. https://doi.org/10.3390/jcdd12060211
Vancouver
Saricaoglu MC, Kandemir M, Saricaoglu EM, Karacuha AF, Kadiroglu E, Abdullahi MF, et al. Driveline Relocation and Vacuum-Assisted Closure for Ventricular Assist Device Driveline Infections. Journal of Cardiovascular Development and Disease. 2025;12(6):211. doi:10.3390/jcdd12060211
BibTeX
@article{Saricaoglu2025,
author = {Saricaoglu, Mehmet Cahit and Kandemir, Melisa and Saricaoglu, Elif M and Karacuha, Ali Fuat and Kadiroglu, Ezel and Abdullahi, Mustafa Farah and Inan, Mustafa Bahadir and Azap, Alpay and Akar, Ahmet Ruchan},
title = {Driveline Relocation and Vacuum-Assisted Closure for Ventricular Assist Device Driveline Infections},
journal = {Journal of Cardiovascular Development and Disease},
year = {2025},
volume = {12},
number = {6},
pages = {211},
doi = {10.3390/jcdd12060211}
}
EUVIMED